Frequency of neutrophils and monocytes in PBMCs.

<p>PBMCs were isolated by density gradient from the blood of controls (n = 10) and LCL patients (n = 15) and the frequencies of CD15⁺ (A), CD14⁺ (B) cells and the ratio of CD15/CD14 (C) were determined by flow cytometry. Values represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney test, ns = not significant.</p

Ratio of CD4/CD8⁺ T cells in PBMCs isolated from controls (n = 10) and LCL patients (n = 12).

<p>Values represent median ± sem.</p

Arginase activity in skin lesions from controls and LCL patients.

<p>Skin biopsies from controls (n = 6) and LCL patients (n = 10) were homogenized and the activity of arginase was measured by enzymatic assay. Values represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney test.</p

Arginase activity in PBMCs from controls and LCL patients.

<p>PBMCs from controls (n = 10) and LCL patients (n = 11) were isolated by Ficoll gradient and the activity of arginase was measured by enzymatic assay. Values represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney test, ns = not significant.</p

Arginase-expressing cells in biopsy are neutrophils.

<p>The phenotype of arginase-expressing cells in homogenates of skin biopsies was determined by flow cytometry by using a combination of antibodies against CD14, CD15 and arginase. Data show the results of one representative experiment out of three independent experiments.</p

Frequency of CD4⁺ and CD8⁺ T cells in PBMCs and biopsies of LCL patients.

<p>The frequencies of CD4⁺ and CD8⁺ T cells was determined in cells isolated from the blood and from the biopsies of LCL patients (n = 15) by flow cytometry. (A) % of CD4⁺ T cells; (B) % of CD8⁺ T cells; (C) ratio of CD4/CD8. Values represent median with interquartile range. Statistical significance was determined by a two-tailed Mann-Whitney test, ns = not significant.</p

CD3ζ and CD8 MFI in PBMCs and biopsies of LCL patients.

<p>The MFI of CD3ζ in CD8⁺ T cells (A) and MFI of CD8 molecule (D) were compared between cells isolated from the blood and from the biopsies of LCL patients (n = 12) by flow cytometry; (B) representative histogram of MFI of CD3ζ in CD8⁺ T cells (open histogram = biopsies, closed histogram = PBMCs); (E) representative histogram of MFI of CD8 (open histogram = biopsies, closed histogram = PBMCs); (C) % decrease in CD3ζ MFI in CD8 (black bar = median); (F) % decrease in CD8. Statistical significance was determined by a Wilcoxon paired test.</p

CD3ζ and CD4 MFI in PBMCs and biopsies of LCL patients.

<p>The MFI of CD3ζ in CD4⁺ T cells (A) and MFI of CD4 molecule (D) were compared between cells isolated from the blood and from the biopsies of LCL patients (n = 12) by flow cytometry; (B) representative histogram of MFI of CD3ζ in CD4⁺ T cells (open histogram  =  biopsies, closed histogram = PBMCs); (E) representative histogram of MFI of CD4 (open histogram = biopsies, closed histogram = PBMCs); (C) % decrease in CD3ζ MFI in CD4 (black bar = median); (F) % decrease in CD4. Statistical significance was determined by a Wilcoxon paired test.</p

Clinical data.

<p>nd = not done.</p

Arginase-expressing cells in PBMCs are neutrophils.

<p>PBMCs were isolated by density gradient from the blood of LCL patients. The phenotype of arginase-expressing cells was determined by flow cytometry. (A) Dot plot profile of CD15⁺ arginase⁺ cells; (B) dot plot profile of CD14⁺ arginase⁺ cells; (C) dot plot profile of forward (FSC) and side scatter (SSC). Data show the results of one representative experiment out of 15 independent experiments. Isotype control for arginase: 0.98%.</p